Neovacs S.A.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a ALNEV.PA research report →
About the company
Based in Paris, France, Neovacs S. A. is a biotechnology firm established in 1993, dedicated to creating therapeutic vaccines for a range of conditions including autoimmune, inflammatory, allergic, and oncological diseases.
- CEO
- Hugo Brugiere
- IPO
- 2010
- Employees
- 22
- HQ
- Paris, FR
Price Chart
- Market Cap
- $89
- P/E
- -0.00
- P/S
- 0.00
- P/B
- 0.00
- EV/EBITDA
- 0.03
- Div Yield
- 0.00%
- Gross Margin
- 11.58%
- Op Margin
- -1846.44%
- Net Margin
- -8984.51%
- ROE
- -106.38%
- ROIC
- -35.84%
- Revenue
- $366.35K · -31.32%
- Net Income
- $-32,914,409 · -276.45%
- EPS
- $-1886061.00 · 99.92%
- Op Income
- $-6,764,344
- FCF YoY
- -73.91%
- 52W High
- $34000.00
- 52W Low
- $1.89
- 50D MA
- $2.36
- 200D MA
- $288.19
- Beta
- -0.21
- Avg Volume
- 4.18K
Get TickerSpark's AI analysis on ALNEV.PA
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Our ALNEV.PA coverage
Recent articles, reports, and earnings notes.
No research on ALNEV.PA yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate ALNEV.PA report →Similar companies
Peers in the same neighborhood.